Tregs, denoted by increased expression of Foxp3, Ctla4, and Tnfrsf4 (CD134), represented 4.5% of sensitive tumor T cells compared to half as many (2.3%) in the resistant populations. This evidence concerns the gene TNFRSF4 and neoplasm.